Our first release, Ceregram: CASBA, is a cutting-edge software platform that converts individual EEG recordings into patient reports with precise estimates of amyloid, tau, and cognitive decline. Ceregram even generates full-resolution PET image estimates—all without the cost or safety concerns of traditional methods. Making complete disease progression monitoring fast, easy, and reliable.

Accepting all inquiries at info@vistimlabs.com

PET vs EEG. Can you tell the difference?

Frequently Asked Questions

Is this qEEG?

No. While qEEG uses frequency analysis to infer arbitrary measures like “concentration” and “attention,” Ceregram operates on an entirely different level. Our patented evoked potential tomography approach sequentially activates neuron columns, one at a time, enabling individual evaluation of the physiological integrity of each column. Combining these insights into a detailed brain map enables brain imaging, which qEEG cannot offer. Preliminary research suggests this method could be more accurate than PET for diagnosis.

Is this PET?

No, Ceregram does not rely on positron emission. However, it functionally mirrors PET’s ability to detect, assess, and quantify amyloid deposits. Ceregram identifies these deposits through their impact on the functional integrity of neuron columns, offering a non-invasive alternative to PET with comparable precision.

Is this doing more than PET?

Yes. Unfortunately, PET is a powerful but limited procedure, that can often only evaluate one endpoint at a time (in rare cases, two). Additionally, these endpoints are only proteins and these proteins do not correlate well with other endpoints: MRI, cognitive assessment results, and more. Ceregram provides reliable estimates for every endpoint. Protein or otherwise.

Is this a reliable way to track disease progression?

Yes! Our studies consistently show an error rate smaller than the natural month-to-month variability of disease biomarkers. This makes Ceregram a reliable method for tracking disease progression over time.

Where can I get a Ceregram scan?

Ceregram is available to partner dementia treatment facilities. Speak with your doctor to find out if Ceregram is available in their clinic or if they can provide a referral. You can also leave your contact information in our web form on the contact page.

How is this different from an amyloid blood test?

While blood tests offer an affordable alternative to PET, they often produce false positives and cannot localize or quantify amyloid deposits. For that reason, these blood tests are most often used to screen patients, but they fail for routine monitoring. Ceregram overcomes these limitations with the necessary precision and spatial resolution for proper understanding of disease and treatment effects. This ensures that any progress seen is reflected symptomatically. In other words: clearing of amyloid in the blood says little about the functional health of neurons in the brain.

Can I see my brain map?

Not yet. In this initial release, brain maps are used internally by our machine learning algorithms to generate traditional biomarker estimates, such as full-resolution PET images. Since clinicians are more familiar with interpreting PET and MRI, our first goal is to ensure these estimates seamlessly integrate into current practices. As we build awareness and evidence, we plan to release brain maps directly for clinical use. These brain maps could become the first direct biomarkers for Alzheimer’s and Parkinson’s, transforming how these diseases are understood and treated.

Is this FDA Compliant?

Yes, our product is fully FDA compliant. The hardware is FDA approved and the software is registered under 510k exemption.